title: Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial.
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of a single intraarticular (IA) injection of hyaluronic acid (HA) for the treatment of hip osteoarthritis (OA).
  
  
  METHODS
  A multicenter, randomized, parallel-group, placebo-controlled trial was conducted over 3 months. Patients (older than 30 years) with symptomatic hip OA (pain score of >40 mm on a visual analog scale [VAS]) and a Kellgren/Lawrence grade of 2 or 3 were randomly assigned to receive 1 fluoroscopically guided IA injection of HA (2.5 ml) or placebo (2.5 ml). Patients were followed up for 3 months. The main outcome measure was pain score on a VAS (100 mm) at month 3 compared with baseline. Secondary outcome measures were the proportion of responders defined by Osteoarthritis Research Society International criteria; Western Ontario and McMaster Universities Osteoarthritis Index subscores for pain, stiffness, and disability; and patient and physician global assessment. Randomization was computer generated. HA and placebo preparations were placed in numbered identical containers, and syringes were covered with masking tape. Physicians assessing outcomes were blinded with regard to group assignment.
  
  
  RESULTS
  Eighty-five patients were randomized to the HA group (n = 42) or placebo group (n = 43). Baseline characteristics were similar between the 2 groups. At 3 months, the decrease in pain score did not differ between the HA and placebo groups in the intent-to-treat analysis (mean +/- SD decrease 7.8 +/- 24.9 mm with HA versus 9.1 +/- 27.4 mm with placebo; P = 0.98). The responder rates were 33.3% and 32.6% in the HA and placebo groups, respectively (P = 0.94). Other secondary end points did not differ between the groups, nor did use of rescue medication or frequency of adverse events.
  
  
  CONCLUSIONS
  Our findings indicate that a single IA injection of HA is no more effective than placebo in treating the symptoms of hip OA.
authors.affiliation: Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Richette
authors.forename: Philippe
authors.initials: P
authors.lastname: Ravaud
authors.forename: Thierry
authors.initials: T
authors.lastname: Conrozier
authors.forename: Liana
authors.initials: L
authors.lastname: Euller-Ziegler
authors.forename: Bernard
authors.initials: B
authors.lastname: Mazières
authors.forename: Yves
authors.initials: Y
authors.lastname: Maugars
authors.forename: Denis
authors.initials: D
authors.lastname: Mulleman
authors.forename: Pierre
authors.initials: P
authors.lastname: Clerson
authors.forename: Xavier
authors.initials: X
authors.lastname: Chevalier
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D015207:Osteoarthritis, Hip / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D010147:Pain Measurement; D016896:Treatment Outcome; D055675:Viscosupplements / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D055675:Viscosupplements; D006820:Hyaluronic Acid